BioNTech SE stated its income from the Covid-19 shot it sells along with Pfizer Inc. could also be decrease this yr than final, predicting gross sales between 13 billion euros and 17 billion euros ($14.7 billion and $19.3 billion).
The corporate stated Covid vaccine gross sales final yr will complete 16 billion euros to 17 billion euros. It issued the 2022 prediction in an investor presentation on Tuesday and is because of launch fourth-quarter monetary knowledge on March 30.
Pfizer in December forecast vaccine gross sales of $31 billion this yr, based mostly on contracts for 1.9 billion doses signed by way of mid-November. The income is shared between the companions. The wave of infections as a result of extremely transmissible omicron variant has intensified booster campaigns in Europe and the U.S., although it’s nonetheless not clear what number of international locations will pursue yet one more spherical of photographs later within the yr.
BioNTech rose 0.7% in Frankfurt after initially dipping on the information.
On Monday, Covid vaccine competitor Moderna Inc. stated it had signed buy agreements value $18.5 billion for this yr, together with choices for one more $3.5 billion.
Extra tales like this can be found on bloomberg.com
©2022 Bloomberg L.P.
This story has been revealed from a wire company feed with out modifications to the textual content. Solely the headline has been modified.
Supply: Live Mint